Allogene Therapeutics (ALLO) Scheduled to Post Quarterly Earnings on Wednesday

Allogene Therapeutics (NASDAQ:ALLO) is scheduled to be posting its quarterly earnings results after the market closes on Wednesday, August 7th. Analysts expect Allogene Therapeutics to post earnings of ($0.35) per share for the quarter.

Allogene Therapeutics (NASDAQ:ALLO) last announced its quarterly earnings results on Monday, May 13th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.03. The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.01 million. Allogene Therapeutics had a negative net margin of 223,139.98% and a negative return on equity of 50.81%. Allogene Therapeutics’s quarterly revenue was down 26.7% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.68) EPS. On average, analysts expect Allogene Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Allogene Therapeutics Trading Down 1.0 %

Allogene Therapeutics stock opened at $2.94 on Thursday. The company has a market capitalization of $614.46 million, a P/E ratio of -1.64 and a beta of 0.85. The firm’s fifty day simple moving average is $2.56 and its 200-day simple moving average is $3.44. Allogene Therapeutics has a 1-year low of $2.01 and a 1-year high of $5.78.

Insider Activity at Allogene Therapeutics

In related news, Director Arie Belldegrun bought 1,724,137 shares of the business’s stock in a transaction that occurred on Thursday, May 16th. The stock was purchased at an average cost of $2.90 per share, for a total transaction of $4,999,997.30. Following the purchase, the director now directly owns 1,724,137 shares in the company, valued at $4,999,997.30. The purchase was disclosed in a filing with the SEC, which is available through this link. In related news, Director Arie Belldegrun bought 1,724,137 shares of the business’s stock in a transaction that occurred on Thursday, May 16th. The stock was purchased at an average cost of $2.90 per share, for a total transaction of $4,999,997.30. Following the purchase, the director now directly owns 1,724,137 shares in the company, valued at $4,999,997.30. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, Director Franz B. Humer sold 11,200 shares of the company’s stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $2.34, for a total transaction of $26,208.00. Following the transaction, the director now owns 255,253 shares of the company’s stock, valued at $597,292.02. The disclosure for this sale can be found here. Corporate insiders own 24.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on ALLO shares. HC Wainwright cut their price target on shares of Allogene Therapeutics from $10.00 to $9.00 and set a “buy” rating on the stock in a report on Thursday, May 16th. Truist Financial restated a “buy” rating and set a $17.00 price target on shares of Allogene Therapeutics in a report on Wednesday, May 15th. Stifel Nicolaus raised their price target on shares of Allogene Therapeutics from $4.40 to $4.60 and gave the company a “hold” rating in a report on Tuesday, May 14th. Oppenheimer cut their price target on shares of Allogene Therapeutics from $14.00 to $13.00 and set an “outperform” rating on the stock in a report on Tuesday, May 21st. Finally, Piper Sandler started coverage on shares of Allogene Therapeutics in a report on Friday, May 31st. They set an “overweight” rating and a $11.00 price target on the stock. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, Allogene Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.95.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).